Phenotype
|
Fish
|
Conditions
|
Figures
|
cardioblast migration disrupted, abnormal
|
AB + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. 3
from Muto et al., 2011
|
blood circulation disrupted, abnormal
|
AB + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. S7
from Muto et al., 2011
|
pericardium edematous, abnormal
|
AB + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. 2 ,
Fig. S7
from Muto et al., 2011
|
pectoral fin bud embryonic pectoral fin morphogenesis decreased process quality, abnormal
|
AB + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. 4 ,
Fig. 5
from Muto et al., 2014
|
apical ectodermal ridge pectoral fin bud embryonic pectoral fin morphogenesis decreased process quality, abnormal
|
AB + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. 2
from Muto et al., 2014
|
nucleate erythrocyte increased accumulation intermediate cell mass of mesoderm, abnormal
|
AB + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. S7
from Muto et al., 2011
|
gut absent, abnormal
|
AB + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. 3
from Muto et al., 2011
|
nucleate erythrocyte increased accumulation yolk anatomical surface, abnormal
|
AB + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. S7
from Muto et al., 2011
|
pectoral fin decreased length, abnormal
|
AB + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. 1
from Muto et al., 2014
|
whole organism endodermal cell decreased amount, abnormal
|
AB + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. 4
from Muto et al., 2011
|
cloacal chamber non-functional, abnormal
|
AB + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. S4
from Muto et al., 2011
|
pectoral fin cartilage malformed, abnormal
|
AB + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. 1
from Muto et al., 2014
|
gut decreased thickness, abnormal
|
AB + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. 3
from Muto et al., 2011
|
hyosymplectic cartilage decreased amount, abnormal
|
AB + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. S5
from Muto et al., 2011
|
left/right pattern formation disrupted, abnormal
|
AB + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. 7
from Muto et al., 2011
|
heart looping disrupted, abnormal
|
AB + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. 3
from Muto et al., 2011
|
heart tube aplastic, abnormal
|
AB + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. 3
from Muto et al., 2011
|
gut malformed, abnormal
|
AB + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. 3
from Muto et al., 2011
|
pectoral fin bud decreased size, abnormal
|
AB + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. 1
from Muto et al., 2014
|
pectoral fin endoskeletal disc chondrocyte disorganized, abnormal
|
AB + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. 1
from Muto et al., 2014
|
pectoral fin bud physical object quality, abnormal
|
AB + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. 3
from Muto et al., 2014
|
fin fold pectoral fin bud embryonic pectoral fin morphogenesis decreased process quality, abnormal
|
AB + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. 2
from Muto et al., 2014
|
pectoral fin bud regulation of smoothened signaling pathway process quality, abnormal
|
AB + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. 3
from Muto et al., 2014
|
positive regulation of DNA-templated transcription decreased process quality, abnormal
|
AB + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. 9
from Muto et al., 2014
|
embryonic pectoral fin morphogenesis decreased process quality, abnormal
|
AB + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. 1
from Muto et al., 2014
|
heart jogging disrupted, abnormal
|
AB + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. 3
from Muto et al., 2011
|
post-vent region decreased length, abnormal
|
AB + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. 2
from Muto et al., 2011
|
heart tube bifurcated, abnormal
|
AB + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. 3
from Muto et al., 2011
|
head decreased size, ameliorated
|
WT + MO1-nipbla + MO1-nipblb
|
chemical treatment: L-leucine zwitterion
|
Fig. 2
from Xu et al., 2015
|
head decreased size, ameliorated
|
WT + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. 8
from Xu et al., 2015
|
cell population proliferation increased occurrence, abnormal
|
WT + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. 7
from Xu et al., 2015
|
heart edematous, abnormal
|
WT + MO1-nipbla + MO1-nipblb
|
chemical treatment: L-leucine zwitterion
|
Fig. S7
from Xu et al., 2015
|
cranial cartilage cartilage development decreased process quality, ameliorated
|
WT + MO1-nipbla + MO1-nipblb
|
chemical treatment: L-leucine zwitterion
|
Fig. 5
from Xu et al., 2015
|
whole organism lethal (sensu genetics), ameliorated
|
WT + MO1-nipbla + MO1-nipblb
|
chemical treatment: L-leucine zwitterion
|
Fig. S4
from Xu et al., 2015
|
head decreased size, ameliorated
|
WT + MO1-nipbla + MO1-nipblb
|
chemical treatment: 4-methyl-2-oxopentanoic acid
|
Fig. 8
from Xu et al., 2015
|
cell population proliferation increased occurrence, ameliorated
|
WT + MO1-nipbla + MO1-nipblb
|
chemical treatment: L-leucine zwitterion
|
Fig. 7
from Xu et al., 2015
|
head apoptotic process increased occurrence, ameliorated
|
WT + MO1-nipbla + MO1-nipblb
|
chemical treatment: L-leucine zwitterion
|
Fig. 6
from Xu et al., 2015
|
whole organism decreased length, abnormal
|
WT + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. 1
from Xu et al., 2015
|
eye decreased size, ameliorated
|
WT + MO1-nipbla + MO1-nipblb
|
chemical treatment: L-leucine zwitterion
|
Fig. 2
from Xu et al., 2015
|
translation decreased process quality, abnormal
|
WT + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. 3,
Fig. 4,
Fig. 9
from Xu et al., 2015
|
whole organism lethal (sensu genetics), abnormal
|
WT + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. 8,
Fig. S4
from Xu et al., 2015
|
trunk decreased length, ameliorated
|
WT + MO1-nipbla + MO1-nipblb
|
chemical treatment: L-leucine zwitterion
|
Fig. 2
from Xu et al., 2015
|
head apoptotic process increased occurrence, abnormal
|
WT + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. 6
from Xu et al., 2015
|
eye decreased size, abnormal
|
WT + MO1-nipbla + MO1-nipblb
|
chemical treatment: 4-methyl-2-oxopentanoic acid
|
Fig. 8
from Xu et al., 2015
|
cranial cartilage cartilage development disrupted, abnormal
|
WT + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. 5
from Xu et al., 2015
|
post-vent region apoptotic process increased occurrence, ameliorated
|
WT + MO1-nipbla + MO1-nipblb
|
chemical treatment: L-leucine zwitterion
|
Fig. 6
from Xu et al., 2015
|
rRNA transcription decreased process quality, ameliorated
|
WT + MO1-nipbla + MO1-nipblb
|
chemical treatment: L-leucine zwitterion
|
Fig. 4
from Xu et al., 2015
|
rRNA transcription decreased process quality, abnormal
|
WT + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. 4,
Fig. 9
from Xu et al., 2015
|
post-vent region curved, ameliorated
|
WT + MO1-nipbla + MO1-nipblb
|
chemical treatment: L-leucine zwitterion
|
Fig. 2
from Xu et al., 2015
|
translation decreased process quality, ameliorated
|
WT + MO1-nipbla + MO1-nipblb
|
chemical treatment: L-leucine zwitterion
|
Fig. 3,
Fig. 4
from Xu et al., 2015
|
heart contraction decreased rate, abnormal
|
WT + MO1-nipbla + MO1-nipblb
|
chemical treatment: L-leucine zwitterion
|
Fig. S7
from Xu et al., 2015
|
post-vent region curved, abnormal
|
WT + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. 1
from Xu et al., 2015
|
embryo development disrupted, abnormal
|
WT + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. 8
from Xu et al., 2015
|
head decreased size, abnormal
|
WT + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. 1
from Xu et al., 2015
|
eye decreased size, abnormal
|
WT + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. 1,
Fig. 8
from Xu et al., 2015
|
heart contraction decreased rate, abnormal
|
WT + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. S7
from Xu et al., 2015
|
rRNA transcription decreased process quality, ameliorated
|
WT + MO1-nipbla + MO1-nipblb
|
chemical treatment: 4-methyl-2-oxopentanoic acid
|
Fig. 9
from Xu et al., 2015
|
embryo development disrupted, ameliorated
|
WT + MO1-nipbla + MO1-nipblb
|
chemical treatment: 4-methyl-2-oxopentanoic acid
|
Fig. 8
from Xu et al., 2015
|
heart edematous, abnormal
|
WT + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. 1,
Fig. S7
from Xu et al., 2015
|
translation decreased process quality, ameliorated
|
WT + MO1-nipbla + MO1-nipblb
|
chemical treatment: 4-methyl-2-oxopentanoic acid
|
Fig. 9
from Xu et al., 2015
|
whole organism lethal (sensu genetics), ameliorated
|
WT + MO1-nipbla + MO1-nipblb
|
chemical treatment: 4-methyl-2-oxopentanoic acid
|
Fig. 8
from Xu et al., 2015
|
post-vent region apoptotic process increased occurrence, abnormal
|
WT + MO1-nipbla + MO1-nipblb
|
standard conditions
|
Fig. 6
from Xu et al., 2015
|
embryonic pectoral fin morphogenesis decreased process quality, abnormal
|
AB + MO1-nipbla + MO1-nipblb + MO5-med12
|
standard conditions
|
Fig. 8
from Muto et al., 2014
|
pectoral fin decreased length, abnormal
|
AB + MO1-nipbla + MO1-nipblb + MO5-med12
|
standard conditions
|
Fig. 8
from Muto et al., 2014
|
pectoral fin bud embryonic pectoral fin morphogenesis decreased process quality, abnormal
|
AB + MO1-nipbla + MO1-nipblb + MO5-med12
|
standard conditions
|
Fig. 8
from Muto et al., 2014
|